Business Wire

METI will hold GGX x TCFD Summit

Share

From 10:00 on October 2 (Mon.), the Ministry of Economy, Trade and Industry (METI) will hold the Global Green Transformation (GGX) Conference and the TCFD Summit, which until now have attracted participation from a wide range of sectors including global industry, finance, governments, regulators, and international organizations, will be held jointly. In order to further develop discussions on transition finance, avoided emissions, industry decarbonization, and other topics related to how business and finance contribute to decarbonization, the event will promote mutual cooperation between the government, business, and financial sectors, and hold discussions to lead the international rule-making process to achieve both emission reductions and economic growth.

  • Outline of Global Green Transformation (GGX) Conference and the TCFD Summit

Date: October 2nd, 2023 10:00-17:00 (JST)
Organizer: Ministry of Economy, Trade and Industry (METI)
Co-organizer: TCFD Consortium, The World Business Council for Sustainable Development (WBCSD)
Format: Hybrid (On-Site and On-Line)
Web Site: https://tcfd-summit.go.jp/indexEn.html

  • Online Registration

Online Registration Site: https://jcs.eventsair.com/ggxtcfd2023/attendeereg/Site/Register
*Registration deadline: Oct 1st (Sun.) (JST, GMT+9:00)

  • Program
  • Opening Remarks
    HATAKEYAMA Yojiro (Director-General, Industrial Science, Technology and Environment Policy Bureau, Ministry of Economy, Trade and Industry)
    TOKURA Masakazu (Chairman, Keidanren (Japan Business Federation))
    KATO Masahiko (Chairperson, Japanese Bankers Association)
    David Atkin (CEO, Principles for Responsible Investment (PRI))
  • Keynote Speech 1
    Gianluigi Benedetti (Ambassador, Embassy of Italy in Tokyo)
  • Panel Discussion 1 “Towards Net-Zero Society ~Industrial Decarbonisation~”
    What efforts are needed towards creating a "Green Market" to accelerate industrial decarbonization, focusing on the creation of demand?
    [Moderator]
    Peter Bakker (President and CEO, World Business Council for Sustainable Development (WBCSD))
    [Panelist]
    Nancy Gillis (Program Head, First Movers Coalition, World Economic Forum)
    Rana Ghoneim (Chief, Energy Systems and Industrial Decarbonization Unit, United Nations Industrial Development Organization)
    TEZUKA Hiroyuki (Fellow, Executive, JFE Steel Corporation)
    MITA Noriyuki (Vice President, Sustainability Department, Mitsubishi Chemical Group Corporation *After October 1st)
    KOBAYASHI Izuru (Deputy Director-General for Environmental Affairs, Ministry of Economy, Trade and Industry)
  • Panel Discussion 2 “Solution Provider and Avoided Emissions”
    Companies are increasingly expected to provide solutions to social challenges. What is the potential of the idea of "avoided emissions" to evaluate a company's contribution to decarbonization of the society as a whole by providing solutions?
    [Moderator]
    HAYASHI Reiko (Director and Deputy President, BofA Securities Japan Co., Ltd.)
    [Panelist]
    Jason Mortimer (Head of Sustainable Investment - Fixed Income, Investment Department - Global Solutions, Nomura Asset Management)
    UEHARA Hirotoshi (Executive Officer, Quality & Environment, CS, Panasonic Operational Excellence Co., Ltd.)
    HIRUTA Takako (Country Leader, CS&Q, Schneider Electric Japan, Inc)
  • Keynote Speech 3
    Emmanuel Faber (Chair, ISSB)
    MIYAZONO Masataka (President, Government Pension Investment Fund)
    MIZUNO Hiromichi (Founder And CEO, Good Steward Partners, LLC)
  • Panel Discussion 3 “Future of Climate-Related Financial Disclosures”
    As climate-related financial disclosures rapidly expand, what efforts are needed going forward? How can disclosure promote transition finance?
    [Moderator]
    NAGAMURA Masaaki (Fellow, International Initiatives, Tokio Marine Holdings, Inc.)
    [Panelist]
    Alex Michie (Head of Secretariat, GFANZ)
    IKEDA Satoshi (Chief Sustainable Finance Officer, Strategy Development And Management Bureau, Financial Services Agency)
    ISHIKAWA Tomohiro (Chief Regulatory Engagement Officer, Corporate Planning Division, Mitsubishi UFJ Financial Group (MUFG))
    KITAGAWA Keiko (General Manager, Sustainability Promotion Unit, Global Investor Relations Group, Finance Strategy and Planning Division, JERA Co., Inc.)
  • Keynote Speech 4
    Mary Schapiro (Head, The TCFD Secretariat)
    ITO Kunio (Chair, The TCFD Consortium)
  • Panel Discussion 4 “Further Promotion of Transition Finance”
    As the understanding of the importance of transition finance grows globally, what efforts are needed to further promote investments toward decarbonization of corporates and the private financing towards them?
    [Moderator]
    KIHARA Shinichi (Director General for International Policy on Carbon Neutrality, Ministry of Economy, Trade and Industry)
    [Panelist]
    Nicholas Pfaff (Deputy Chief Executive, Head of Sustainable Finance, International Capital Market Association)
    Sean Kidney (CEO, Climate Bonds Initiative)
    Eila Kreivi (Director, Chief Sustainable Finance Advisor, Secretariat General, European Investment Bank)
    KUBOTA Nobuhiko (Managing Executive Officer, General Manager of Technology & Intelligence Integration, IHI Corporation)
  • Closing Remarks
    Peter Bakker (President and CEO, World Business Council for Sustainable Development (WBCSD))

*The above programs and speakers may be subject to change at the discretion of the organizer.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contact information for inquiries
GGX x TCFD Summit 2023 Registration Desk
E-mail: ggxtcfd2023-reg@convention.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye